Impact and innovation

Driving innovation in the economic sustainability of health systems

We search for innovative solutions to healthcare challenges. Our novel ‘productivity adjusted life year’ (PALY) measure allows for estimation of the broader economic impact of diseases and interventions. We’ve also examined avenues to reduce low-value healthcare, and have estimated the return on investment from increasingly popular clinical registries. We’re currently exploring new models for funding healthcare, the need for which is highlighted by ageing populations, growing multi-morbidity and rising costs.

Our impact

Work conducted by our team members has underpinned changes to clinical guidelines, practice and policy across a broad range of health issues. Our commercial-in-confidence projects have led to the reimbursement of a multitude of drugs, other interventions and health services both in Australia and overseas.


Genetic screening for familial hypercholesterolaemia was listed as a reimbursable item in Australia, and routine family screening commenced in Western Australia as a result of a cost-effectiveness study completed by our team. The cardiovascular drugs eplerenone and rivaroxaban have also been publicly reimbursed in Australia following our demonstration of their cost-effectiveness.

We’ve estimated the burden of osteoarthritis in Australia, work that has been used to justify several major policy documents, including the Australian Commission on Safety & Quality in Healthcare’s Clinical Care Standards, the Victorian Model of Care, the National Plan for Arthritis and the National Osteoarthritis Strategy. Other osteoarthritis research we’ve completed has enabled international registries to benchmark and monitor the rising use of joint replacement surgery, and new data we produced led to current trials aimed at reducing knee injuries in women footballers.

Finally, our work has contributed to the establishment and rollout of the Australian Orthopaedic Association National Joint Replacement Registry Patient-Reported Outcome Measures Program, collecting PROMs data on joint replacement outcomes since 2017.


The Federal Government’s record Medicare rebate freeze was overturned in part by the Federal Opposition’s Medicare Policy, which cited this paper. The Commonwealth government announced a $50million investment in rural health medical training in their FY2020/21 budget after a commissioned evaluation of the nation’s current program involving A/Prof Callander.


Current maternity department staffing in Queensland’s public health system is being informed by analysis produced by Assoc Prof Callander. In 2021, Queensland Health designed its new strategy, in partnership with Assoc Prof Callander, to promote natural births and reduce unnecessary caesareans following this analysis. In 2019, fibronectin testing was incorporated into routine management of threatened pre-term delivery in remote Queensland communities, in part based on this investigation.

Assoc Prof Callander has also led or contributed to components in a significant body of work to understand or reduce stillbirth in Australia, including estimates of direct health and macroeconomic costs, development and near-national delivery of a stillbirth reduction tools including My Baby’s Movements mobile app and the Safer Baby Bundle.


Pill Protect®, a genetic screening tool to identify women at increased risk of blood clots associated with oral contraceptive pill use, was shown to be cost-effective in Switzerland, leading to reimbursement decisions in Switzerland.

Assoc Prof Ademi’s involvement in the health economic domain of Switzerland’s national health technology assessment has influenced health policy decisions in that country covering the treatment of intervertebral disc herniation, bariatric surgery for weight reduction and treatments for Alzheimer’s disease. She’s also been involved in a cost-effectiveness study of the Herpes Zoster vaccine, that similarly has led to a policy decision recommending reimbursement in that country, and another that supported reimbursement for cardiovascular drugs.

Her work evaluating the cost-effectiveness of patiromer in treating chronic kidney disease has resulted in reimbursement and approval of the drug for clinical use in several European countries.

We’ve also contributed evidence that’s driven changes in smoking cessation, diabetes therapies, chronic pain management, use of immune-oncology agents, biological therapies for inflammatory bowel diseases, and immunisation for pneumococcal and meningococcal disease.